Bicycle TherapeuticsBCYC
About: Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Employees: 284
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
108% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 12
100% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 4 (+2) [Q2]
40% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 25
14% more funds holding
Funds holding: 92 [Q1] → 105 (+13) [Q2]
3.82% more ownership
Funds ownership: 84.42% [Q1] → 88.24% (+3.82%) [Q2]
1% more capital invested
Capital invested by funds: $796M [Q1] → $804M (+$7.6M) [Q2]
26% less call options, than puts
Call options by funds: $188K | Put options by funds: $255K
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
JMP Securities Reni Benjamin 21% 1-year accuracy 6 / 28 met price target | 18%upside $32 | Market Outperform Reiterated | 16 Sept 2024 |
HC Wainwright & Co. Swayampakula Ramakanth 22% 1-year accuracy 24 / 109 met price target | 103%upside $55 | Buy Reiterated | 16 Sept 2024 |
Needham Ami Fadia 52% 1-year accuracy 26 / 50 met price target | 40%upside $38 | Buy Reiterated | 16 Sept 2024 |
Needham Ami Fadia 52% 1-year accuracy 26 / 50 met price target | 40%upside $38 | Buy Reiterated | 9 Sept 2024 |
RBC Capital Gregory Renza 66% 1-year accuracy 41 / 62 met price target | 29%upside $35 | Outperform Initiated | 6 Sept 2024 |
Financial journalist opinion
Based on 3 articles about BCYC published over the past 30 days
